[go: up one dir, main page]

NO986088D0 - Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisi - Google Patents

Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisi

Info

Publication number
NO986088D0
NO986088D0 NO986088A NO986088A NO986088D0 NO 986088 D0 NO986088 D0 NO 986088D0 NO 986088 A NO986088 A NO 986088A NO 986088 A NO986088 A NO 986088A NO 986088 D0 NO986088 D0 NO 986088D0
Authority
NO
Norway
Prior art keywords
polypeptides
antigen binding
specificity
ability
binding structures
Prior art date
Application number
NO986088A
Other languages
English (en)
Other versions
NO986088L (no
NO327947B1 (no
Inventor
Sylvia Miescher
Monique Vogel
Beda Stadler
Andreas Morell
Martin Imboden
Hanspeter Amstutz
Original Assignee
Rotkreuzstiftung Zentrallab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rotkreuzstiftung Zentrallab filed Critical Rotkreuzstiftung Zentrallab
Publication of NO986088D0 publication Critical patent/NO986088D0/no
Publication of NO986088L publication Critical patent/NO986088L/no
Publication of NO327947B1 publication Critical patent/NO327947B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
NO19986088A 1996-06-24 1998-12-23 Polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, DNA-sekvenser, fremgangsmater for seleksjon av rekombinante polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, anti-Rhesus D-antistoffer, framgangsmate for fremstilling av fullstendige anti-Rhesus D-antistoffer, farmasoytisk preparat samt diagnostisk preparat for Rhesus D-type bestemmelse NO327947B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96810421 1996-06-24
PCT/EP1997/003253 WO1997049809A1 (en) 1996-06-24 1997-06-20 Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use

Publications (3)

Publication Number Publication Date
NO986088D0 true NO986088D0 (no) 1998-12-23
NO986088L NO986088L (no) 1999-02-24
NO327947B1 NO327947B1 (no) 2009-10-26

Family

ID=8225636

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19986088A NO327947B1 (no) 1996-06-24 1998-12-23 Polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, DNA-sekvenser, fremgangsmater for seleksjon av rekombinante polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, anti-Rhesus D-antistoffer, framgangsmate for fremstilling av fullstendige anti-Rhesus D-antistoffer, farmasoytisk preparat samt diagnostisk preparat for Rhesus D-type bestemmelse

Country Status (23)

Country Link
US (3) US7038020B1 (no)
EP (1) EP0920509B1 (no)
JP (1) JP3841360B2 (no)
KR (1) KR100361449B1 (no)
AT (1) ATE272116T1 (no)
AU (1) AU722127B2 (no)
BG (1) BG64534B1 (no)
BR (1) BR9709958A (no)
CA (1) CA2258494C (no)
CZ (1) CZ296807B6 (no)
DE (1) DE69730031T2 (no)
DK (1) DK0920509T3 (no)
ES (1) ES2224255T3 (no)
HU (1) HUP9902605A3 (no)
IL (1) IL127595A (no)
IS (1) IS2220B (no)
NO (1) NO327947B1 (no)
NZ (1) NZ333329A (no)
PL (1) PL186019B1 (no)
RU (1) RU2204602C2 (no)
SK (1) SK284879B6 (no)
TR (1) TR199802692T2 (no)
WO (1) WO1997049809A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1631000A (en) * 1998-11-19 2000-06-05 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
EP1106625A1 (en) * 1999-11-17 2001-06-13 ZLB Bioplasma AG Rhesus D specific peptide sequences
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US20040029113A1 (en) 2000-04-17 2004-02-12 Ladner Robert C. Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
AU2002226049A1 (en) * 2000-12-05 2002-06-18 Alexion Pharmaceuticals, Inc. Engineered plasmids and their use for in situ production of genes
PT2316940E (pt) 2000-12-18 2013-10-16 Dyax Corp Bibliotecas orientadas de pacotes genéticos
AU2016225923B2 (en) * 2001-04-17 2018-07-05 Takeda Pharmaceutical Company Limited Novel Methods of Constructing Libraries Comprising Displayed and/or Expressed Members of a Diverse Family of Peptides, Polypeptides or Proteins and the Novel Libraries
RU2209434C1 (ru) * 2001-11-15 2003-07-27 Российский центр судебно-медицинской экспертизы Министерства здравоохранения Российской Федерации Способ получения резус-пептидов анти-d, специфически выявляющих антиген rhd в следах крови и выделений
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
DK2053408T3 (da) 2004-07-20 2012-06-04 Symphogen As Fremgangsmåde til strukturel karakterisering af et rekombinant polyklonalt protein eller en polyklonal cellelinje
EP1967529A1 (en) * 2004-07-20 2008-09-10 Symphogen A/S Anti-rhesus D recombinant polyclonal antibody and methods of manufacture
GB0706558D0 (en) * 2007-04-03 2007-05-09 Common Services Agency For The Diagnostic assay
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20090093004A1 (en) 2007-10-04 2009-04-09 Symphogen A/S Potency assay
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
AU2009240481B2 (en) 2008-04-24 2015-07-30 Takeda Pharmaceutical Company Limited Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
AU2018350372C9 (en) * 2017-10-20 2025-06-05 Csl Limited Method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2127434A (en) 1982-09-17 1984-04-11 Univ London A human monoclonal antibody against Rhesus D antigen
GB8722018D0 (en) * 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8925590D0 (en) * 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies

Also Published As

Publication number Publication date
NO986088L (no) 1999-02-24
PL186019B1 (pl) 2003-09-30
DE69730031T2 (de) 2005-06-16
IL127595A0 (en) 1999-10-28
BG103016A (en) 1999-08-31
KR100361449B1 (ko) 2003-01-24
SK176198A3 (en) 1999-07-12
DE69730031D1 (de) 2004-09-02
ATE272116T1 (de) 2004-08-15
CA2258494A1 (en) 1997-12-31
KR20000022530A (ko) 2000-04-25
ES2224255T3 (es) 2005-03-01
US7429647B2 (en) 2008-09-30
PL330794A1 (en) 1999-06-07
HUP9902605A3 (en) 2001-11-28
US7399471B2 (en) 2008-07-15
BG64534B1 (bg) 2005-06-30
RU2204602C2 (ru) 2003-05-20
BR9709958A (pt) 1999-08-10
EP0920509B1 (en) 2004-07-28
WO1997049809A1 (en) 1997-12-31
IS2220B (is) 2007-03-15
JP3841360B2 (ja) 2006-11-01
CZ395998A3 (cs) 1999-05-12
NZ333329A (en) 2000-07-28
IS4922A (is) 1998-12-11
SK284879B6 (sk) 2006-01-05
AU722127B2 (en) 2000-07-20
EP0920509A1 (en) 1999-06-09
CZ296807B6 (cs) 2006-06-14
US20060165694A1 (en) 2006-07-27
NO327947B1 (no) 2009-10-26
AU3342397A (en) 1998-01-14
IL127595A (en) 2005-09-25
US20050266013A1 (en) 2005-12-01
CA2258494C (en) 2008-05-27
HUP9902605A2 (hu) 1999-11-29
DK0920509T3 (da) 2004-12-06
JP2000515732A (ja) 2000-11-28
TR199802692T2 (xx) 1999-03-22
US7038020B1 (en) 2006-05-02

Similar Documents

Publication Publication Date Title
NO986088D0 (no) Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisi
TR199801722T2 (xx) Peptit imm�nojenler.
WO2002072636A8 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
WO2000037025A3 (en) Antibodies to truncated vegf-d and uses thereof
WO2001093913A3 (en) T cell receptor fusions and conjugates and methods of use thereof
WO1998050547A3 (en) Human toll-like receptor proteins, related reagents and methods
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
DE68925226D1 (de) Monoklonale Antikörper
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
CA2068222A1 (en) Monoclonal antibodies
EP1433792A3 (en) Human receptor proteins, related reagents and methods
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
EP1354896A4 (en) NEW MONOCLONAL ANTIBODY
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO1999002564A3 (de) Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees